Study of the Expression of Met Receptor Fragments in Non Small Cell Lung Cancers

NCT ID: NCT01647867

Last Updated: 2018-03-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

56 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-07-31

Study Completion Date

2016-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Our project, established through collaboration between clinicians (Oscar Lambret Center-University Hospital) and scientists (IBL), aims to evaluate the expression of Met fragments in the lung cancer (LC). Unlike previous studies on Met by sequencing, in situ hybridization or immunohistochemistry, the investigators propose a protein analysis by Western blot of tumor samples and healthy tissue. This approach will evaluate the expression of full-length receptor, the potential presence of intracellular fragments, and their phosphorylation status.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

* Patient information and collection of signed inform consent
* Blood sample collection before bronchoscopy or before surgery, at the same time as a usual blood assessment.
* Prospective collection of bronchial biopsies of patients with metastatic non small cell lung cancer, during a bronchoscopy at the Oscar Lambret Center (Dr Dansin)
* Prospective collection of resected specimens of patients with localized non small cell lung cancer, who were operated at the thoracic surgery unit of the University hospital (Pr Porte)
* Transportation of the samples to the pathology laboratories (Dr Robin, Pr Copin)
* Selection of blocks of interest and preparation of tumor samples
* Clinical data collection : date of biopsy or surgery, disease-free survival, overall survival, tumor characteristics, EGFR status, ALK, BRAF, HER2
* Transportation of tumor blocks and blood samples to the Institute of Biology of Lille for analyses: Western blot, immunohistochemistry and ELISA test)
* Return to storage of the tumor samples at the Oscar Lambret Center and at the University hospital of Lille

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non Small Cell Lung Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Met analysis

Met analysis on tissue and blood Western Blot Immunohistochemistry ELISA test

Group Type EXPERIMENTAL

Met analysis on tissue and blood

Intervention Type OTHER

10 mL of blood and 4 pieces of tissue (2 of tumor tissue, 2 of healthy tissue) all taken at the same time as surgery or bronchoscopy, depending on the stage of the disease

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Met analysis on tissue and blood

10 mL of blood and 4 pieces of tissue (2 of tumor tissue, 2 of healthy tissue) all taken at the same time as surgery or bronchoscopy, depending on the stage of the disease

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with non small cell lung cancer (NSCLC)
* Patients candidate for bronchial biopsies at the Oscar Lambret Center (metastatic stage) or candidate for thoracic surgery at University Hospital of Lille (localized stage)
* Treatment naive patient for metastatic NSCLC
* Patients with or without neoadjuvant therapy for localized NSCLC
* Male or female patients aged ≥ 18 years
* Patient registered with the social security system
* Having signed a written Informed Consent

Exclusion Criteria

* Malignant tumors which are not carcinoma
* Small-cell malignant tumors
* Secondary bronchial lesions
* Revision surgery
* Pregnant or breastfeeding women
* Patient under guardianship or tutorship
* Previous cancer
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Centre Oscar Lambret

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Eric DANSIN, MD

Role: STUDY_DIRECTOR

Centre Oscar Lambret

David TULASNE, PhD

Role: STUDY_DIRECTOR

Institute of Biology of Lille

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Centre Hospitalier Régional et Universitaire

Lille, , France

Site Status

Oscar Lambret Center

Lille, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MetLung - 1204

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

PD-L1 Expression in Lung Cancer
NCT04992715 UNKNOWN PHASE2